Two months to the day before its Dec. 24 PDUFA date, Xofluza (baloxavir marboxil, previously S-033188, RG-6152), gained a nod from the FDA to treat acute uncomplicated influenza in individuals 12 and older who became symptomatic within the previous 48 hours.